Corporate Information – Page 26 – Alligator Bioscience

2021-06-07

Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy

Lund, Sweden, June 7, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the scientific journal Expert Opinion on Bi ...

2021-06-04

Regulatory

Lund, Sweden, June 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I cl ...

2021-06-01

Lund, Sweden, June 1, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the annual general meeting was held in the ...

2021-05-05

Lund, Sweden, May 5, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 an ...

2021-05-04

Lund, Sweden, May 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreeme ...

2021-04-30

Lund, Sweden, April 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company's Board member Carl Borre ...

2021-04-26

The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 (“Alligator”), are invited to the annual general meeting to be held on Tue ...

2021-04-22

Regulatory

Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding C ...

2021-04-15

Lund, Sweden, April 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research coll ...